ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email!
Bard Medical Device Company Intelligence Report Published on August 2011
Report Summary Headquartered in Murray Hill, New Jersey, US, C.R. Bard (Bard) develops and manufactures medical, surgical, diagnostic and patient care devices. The company sells its products to hospitals, individual healthcare professionals, extended care health facilities and alternate site facilities in the US and in more than 100 other countries, principally in Europe and Japan. In general, Bard's products are intended to be used once and then discarded or implanted either temporarily or permanently. Bard serves the healthcare industry through five divisions ' Bard Access Systems Inc, Bard Electrophysiology Division, Bard Medical Division, Bard Peripheral Vascular Inc (including Bard Biopsy Systems) and Davol Inc ' and four major product group categories ' vascular, urology, oncology and surgical specialties. The company also has a product group of 'Other Products'.
Vascular ' Bard's vascular products are produced by Bard Electrophysiology and Bard Peripheral Vascular. The company's vascular products cover a wide range of minimally-invasive devices for the treatment of peripheral vascular disease (PVD) and heart arrhythmias. These products include: percutaneous transluminal angioplasty (PTA) catheters, chronic total occlusions (CTO) catheters, guidewires, introducers and accessories; peripheral vascular stents and stent grafts, vena cava filters and biopsy devices; electrophysiology products, including electrophysiology laboratory systems and diagnostic, therapeutic and temporary pacing electrode catheters; and fabrics, meshes and implantable vascular grafts. Bard led the industry with the first angioplasty balloon catheter in 1980, giving cardiologists a safer and less costly alternative to open-heart procedures. The January 2008 acquisition of the LifeStent range of stents from Edwards Lifesciences provided Bard with one of the broadest product offerings for peripheral vascular stenting. The acquisition of Y-Med in November 2009 provided Bard with access to the VascuTrak catheter range. More recently, the acquisition of FlowCardia in April 2010 expanded Bard's portfolio of CTO endovascular products. Urology ' Bard claims to be the worldwide market leader in urological diagnostic and interventional products with a focus on urological drainage, continence and prostate disease management. Through its Bard Medical Division, the company has expanded its urology business to products in the areas of infection control, continence management, prostate management and catheter stabilisation. The Foley catheter, which Bard introduced in 1934, remains one of the most important products in the urological field. Other urology products include: surgical slings used to treat stress urinary incontinence; faecal incontinence products; natural and synthetic devices for the treatment of pelvic floor and vaginal prolapse; brachytherapy services, devices and radioactive seeds used to treat prostate cancer; intermittent urinary drainage catheters, urine monitoring and collection systems; ureteral stents; and specialty devices for ureteroscopic procedures and stone removal. Bard entered the brachytherapy business in March 1998 with the purchase of Proseed Inc, which offered a turnkey programme that allows a hospital to implement brachytherapy treatment with lower investment cost and financial risk. The acquisition of Venetec International in 2006 gave Bard access to the StatLock range of catheter stabilisation devices, which are
Bard Medical Device Company Intelligence Report (From Issuu)
Page 1/8
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! used primarily to secure peripheral intravenous catheters. Oncology ' Bard's oncology products and services are provided through Bard Access Systems, Bard Biopsy Systems and Bard Medical Division. They are designed for the treatment and management of various cancers and other diseases and disorders. These include specialty access catheters and ports; vascular access ultrasound devices, dialysis access catheters and enteral feeding devices. The acquisition of Dymax Corp extended Bard Access Systems' portfolio to include ultrasound systems that allow physicians to have real-time visualisation of needle placement. The purchase of SenoRx in July 2010 enabled Bard to expand its breast biopsy business into the stereotactic X-ray segments. Surgical Specialties ' Bard maintains a complete line of advanced surgical specialty products and services to complement its focus on disease state management. These products are produced by Bard Medical and Davol and include implanted patches and fixation systems for hernia and other soft tissue repairs, irrigation devices for orthopaedic, laparoscopic and gynaecological procedures and products for topical haemostasis. Other Products ' The other product group includes irrigation, wound drainage and certain original equipment manufacturer (OEM) products. Bard employs approximately 11,700 people. In 2010, the company generated net earnings of US$510 million on revenues of US$2.72 billion. Net sales in the first six months of 2011 reached US$1.43 billion.
Bard's shares are traded on the New York Stock Exchange. In August 2011, ValueAct Capital Management, a San Francisco, California-based hedge fund, announced that it held 6.5% of the company's shares. This company report provides: Overview Key contact information Introduction to the company and its current activities Summary of its financial performance Who are the company's major competitors' Key recent events in an 'at a glance' format Financial Review Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available) Table providing in-depth five-year financial analysis Employee data, including breakdown by company division and geographic location Strategic Focus Investigates the company's aims and its areas of focus Products Core product areas, key brands, product approvals and launches Research and Development How much has been invested in R&D' Where is the research based' What alliances and agreements does the company have and with whom' Manufacturing and Distribution
Bard Medical Device Company Intelligence Report (From Issuu)
Page 2/8
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Identifying the company's manufacturing locations Sales and marketing facilities Agreements With whom has the company reached agreements and what do they involve' Key contracts awarded Mergers, Acquisitions, Minority Investments and Divestments Litigation Key Corporate Events
The report was produced as part of Medical Device Companies Analysis (MDCA). For more information on MDCA, click here.
Table of Content
Contents OVERVIEW..1 FINANCIAL REVIEW..3 First Half 2011 Financial Results .3 Vascular 4 Urology .4 Oncology .4 Surgical Specialty ..5 Other ..5 2010 Financial Results5 Vascular 7 Urology .7 Oncology .8 Surgical Specialty ..9 Other ..9 Five-Year Financial Data.10 Outlook..11 Employees11 STRATEGIC FOCUS..12 PRODUCTS..13 Vascular.14 Urology..16
Bard Medical Device Company Intelligence Report (From Issuu)
Page 3/8
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Oncology .18 Surgical Specialty20 RESEARCH AND DEVELOPMENT22 Product Pipeline..22 Studies and Trials 24 RESILIENT Trial24 Bard Flair Endovascular Stent Graft.24 MANUFACTURING AND DISTRIBUTION.26 AGREEMENTS .27 Acacia Research's Catheter Flushing Division27 Covalon Technologies27 RTI Biologics 28 Thermal Scalpel 28 Philips..28 Medegen29 Genzyme29 TyRx Pharma29 Enpath Medical..30 CardioTech International (now AdvanSource Biomaterials)..30 Mentor.30 Tissue Science Laboratories..30 Mediwatch 31 Floreane Medical Implants 31 Specialized Health Products International ..31 Endologix..31 Collagen (Allergan)..31 IS Pharma (formerly Maelor).32 Integra LifeSciences32 MERGERS AND ACQUISITIONS .. 33 Romedex International 33 SenoRx 34 Bard Sendirian34 FlowCardia34 PacerView Technologies Assets..34 Spire Corporation Assets.34 Y-Med34 Brennen Medical..35 Specialized Health Products International..35 LifeStent Product Line from Edwards Lifesciences..35 Inrad.35 Venetec International36 PST's Self-Expanding Stent Assets.36 Genyx Medical36 Sorenson Medical's Closed Suction Catheter System 36 Onux Medical .37 Bridger Biomedical .37 Prostate Services of America, Amertek Medical and Alton Design37 Biomedical Instruments and Products GmbH's Biopsy Device.37
Bard Medical Device Company Intelligence Report (From Issuu)
Page 4/8
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Source Tech Medical37 Imagyn Medical Technologies - Rights to Seed Business.37 NMT Medical's Vena Cava Filter Business..38 Mill-Rose Laboratories .38 Surgical Sense 38 Biosearch Medical Products' Intermittent Urinary Catheter Business Dymax .38 ProSeed..38 Endomatrix ..39 Impra 39 American Hydro-Surgical Instruments ..39 Vas Cath .39 Angiomed .39 Cardial .39 Bainbridge Sciences ..39 JOINT VENTURES .. 40 Medicon..40 MINORITY INVESTMENTS .41 Hydromer .41 DIVESTITURES 42 Endoscopic Technologies Business42 Cardiopulmonary Business 42 Intra-Aortic Balloon Catheter and Pump Business..42 Coronary Cath Lab Business .42 Neonatal Product Line .42 Surgical Suction Product Line..42 Sani-Spec Product Line.43 Sure-Closure System .43 Inspiron Division ..43 MedSystems Division 43 Shield Healthcare Centers .43 Electromedical Systems ..43 LITIGATION 44 Product Liability Matters 44 Hernia Repair Implant Products. 44 Women's Health Products.. 44 Vena Cava Filter Products 45 Hologic45 Atrium Medical and Endologix.45 Covidien.45 W.L. Gore & Associates..45 St Francis Medical Center 46 US Department of Health and Human Services, OIG. KEY CORPORATE EVENTS..47 List of Tables SUMMARY OPERATING RESULTSiii
Bard Medical Device Company Intelligence Report (From Issuu)
Page 5/8
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Recent Key Events..2 Bard - First Half 2011 Financial Results..3 Bard - First Half 2011 Sales by Product Area3 Bard - First Half 2011 Sales by Geographic Area3 Bard - Annual Financial Results, 2006-2010..5 Bard - Annual Sales by Geographic Area, 2006-20106 Bard - Annual Sales by Product Area, 2006-20106 Bard ' Five-Year Financial Summary..10 Bard ' Product Contributions to Net Sales, 2006-2010..13 Key Vascular Products..14 Key Urology Products16 Key Oncology Products.18 Key Surgical Specialty Products20 Bard - Annual R&D Expenditure, 2006-201022 Bard ' Principal Offices and Manufacturing Locations..26 Agreements Summary.27 Mergers and Acquisitions Summary.33 List of Charts Bard - Annual Sales and Operating Income, 2006-2010..5 Bard - Annual Sales by Geographic Area, 2006-20106 Bard - Annual Sales by Product Area, 2006-20107 Bard - 2010 Sales by Product Group..13 Bard - Annual Vascular Product Sales, 2006-201014 Bard - Annual Urology Product Sales, 2006-2010.16 Bard - Annual Oncology Product Sales, 2006-2010..18 Bard - Annual Surgical Specialty Product Sales, 2006-201021
Bard Medical Device Company Intelligence Report (From Issuu)
Page 6/8
Find Industry reports, Company profiles and Market Statistics
ReportLinker
>> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: ƒ ƒ
Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information Please verify that the product information is correct and select the format(s) you require. Bard Medical Device Company Intelligence Report
Product Formats Please select the product formats and the quantity you require. 1 User License--USD 516.25
Quantity: _____
Hard Copy--USD 516.25
Quantity: _____
Department License--USD 1 312.50
Quantity: _____
Site License--USD 2 362.50
Quantity: _____
Corporate License--USD 3 412.50
Quantity: _____
Contact Information Please enter all the information below in BLOCK CAPITALS
Title:
Mr
Mrs
Dr
Miss
Ms
Prof
First Name:
_____________________________ Last Name: __________________________________
Email Address:
__________________________________________________________________________
Job Title:
__________________________________________________________________________
Organization:
__________________________________________________________________________
Address:
__________________________________________________________________________
City:
__________________________________________________________________________
Postal / Zip Code:
__________________________________________________________________________
Country:
__________________________________________________________________________
Phone Number:
__________________________________________________________________________
Fax Number:
__________________________________________________________________________
Bard Medical Device Company Intelligence Report (From Issuu)
Page 7/8
Find Industry reports, Company profiles and Market Statistics
ReportLinker
>> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card
Card Number: ______________________________________________
Expiry Date
__________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer
Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check
UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms
Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Bard Medical Device Company Intelligence Report (From Issuu)
Page 8/8